ClinicalTrials.gg
Active, not recruitingNCT02180724Updated Sep 14, 2026Results posted

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

A Phase 2 interventional study of Acalabrutinib (ACP-196) and Acalabrutinib (ACP-196) in Waldenström Macroglobulinemia (WM), sponsored by Acerta Pharma BV. Active, not recruiting at 38 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Waldenstrom Macroglobulinemia with a site in France — 11 open to participants now, 16 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · France.

Enrollment
23rd of 36
107 · median 130
Started
2014
with 1 other
Phase 2
12 of 41
2 open now
Primary completion
2019-10
later than 0 of 15 live
Registered
17th of 41
by date
Lead sponsor
1 of 41
Acerta Pharma BV

Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, this one is the 23rd largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2014, is one of 12 in phase 2, reaches primary completion later than 0 of the 15 other live ones, and was the 17th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

11 of the 41 studies in Waldenstrom Macroglobulinemia with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Waldenstrom Macroglobulinemia with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

Read the detailed description

Clinical studies have shown that targeting the B-cell receptor (BCR) signaling pathway by inhibiting Bruton tyrosine kinase (BTK) produces significant clinical benefit in patients with non-Hodgkin lymphoma, including Waldenström macroglobulinemia (WM). Ibrutinib (IMBRUVICA®), an oral, small-molecule BTK inhibitor has been approved for the treatment for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and WM.

Acerta Pharma BV (AcertaPharma) has developed a novel BTK inhibitor, acalabrutinib, that achieves significant oral bioavailability and potency in preclinical models.

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

03

Conditions studied

  • Waldenström Macroglobulinemia (WM)

Keywords

  • Bruton tyrosine kinase inhibitor
  • Btk
  • Waldenström Macroglobulinemia
  • WM
  • Waldenström
  • Macroglobulinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥18 years of age.
  2. Previously treated cohort only: A confirmed diagnosis of WM, which has after, or been refractory to ≥1prior therapy for WM and which requires treatment.
  3. Previously untreated cohort only: A confirmed diagnosis of previously untreated WM in subjects who require treatment and do not want to receive chemoimmunotherapy or have comorbidities that would preclude chemoimmunotherapy such as:

    • Symptomatic hyperviscosity with an IgM ≥5,000mg/dL
    • Disease-related neuropathy
  4. Serum concentration of IgM, as measured by SPEP and IFE, that exceeds the or measurable nodal WM (defined as the presence of ≥1lymph node that measures ≥2.0 cm in the longest diameter and ≥1.0cm in the longest perpendicular diameter).
  5. performance status of ≤2.
  6. Women who are sexually active and can bear children must agree to use highly effective forms of during the study and for 2 days after the last dose of acalabrutinib.
  7. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
  8. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Exclusion criteria

Exclusion Criteria:

  1. Prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥2 years or which will not limit survival to \<2 years. Note: These cases must be discussed with the medical monitor.
  2. A life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
  3. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or >480 msec.
  4. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  5. Any immunotherapy within 4 weeks of first dose of study drug.
  6. For subjects with recent chemotherapy or experimental therapy, the first dose of study drug must occur after 5 times the half-life of the agent(s).
  7. Prior exposure to a BCR inhibitor (e.g., BTK,PI3K, or SYK inhibitors) or BCL-2 inhibitors (e.g., ABT-199).
  8. Ongoing therapy, including systemic or enteric for treatment of WM or other conditions. Note: Subjects may use topical or inhaled corticosteroids or low-dose steroids (≤10 mg of prednisone or equivalent per day) as therapy for comorbid conditions. During study participation, subjects may also receive systemic or enteric corticosteroids as needed for treatment-emergent comorbid conditions.
  9. Grade ≥2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.
  10. Known history of or active infection with or virus (HBV) or any uncontrolled active systemic infection.
  11. Major surgery within 4 weeks before first dose of study drug.
  12. Uncontrolled hemolytic anemia or idiopathic thrombocytopenia purpura.
  13. History of a bleeding diathesis (e.g., hemophilia, von Willebrand disease).
  14. History of stroke or intracranial hemorrhage within 6 months before the first dose of acalabrutinib.
  15. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 28 days of first dose of study drug.
  16. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
  17. ANC \<0.75 x 109/L or count \<50 x 109/L. For subjects with disease involvement in the bone marrow, ANC \<0.50 x 109/L or platelet count \<30x109/L.
  18. Creatinine >2.5 x institutional ; total >2.5 x ULN; or or ALT >3.0 x ULN.
  19. Lactating or pregnant.
  20. Concurrent participation in another therapeutic clinical trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Previously Treated

    Subjects previously treated with Waldenström Macroglobulinemia N=92

    Drug: Acalabrutinib (ACP-196)

  • Experimental
    Treatment Naïve

    Subjects with treatment-naïve Waldenström Macroglobulinemia. N=14

    Drug: Acalabrutinib (ACP-196)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria

    ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.

    Time frame: Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).

  2. Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria

    ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.

    Time frame: Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).

Secondary outcomes

  1. Progression-free Survival (PFS) of Acalabrutinib by Investigator

    Kaplan-Meier (K-M) estimates of the PFS assessments and its 95% confidence interval are provided using both modified 3rd and 6th IWWM criteria by investigator. K-M estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive or have not progressed by the given time over all patients at risk. Per 6th IWWM criteria, the progressive disease is defined as \>= 25% increase in serum IgM level with an absolute increase of at least 500 mg/dL from lowest nadir (requires confirmation on at least 2 consecutive measurements at least 4 weeks apart) and/or progression of clinical features attributable to the disease. Per modified 3rd IWWM criteria, besides IgM requirement as 6th criteria, it could also includes progression of clinically significant disease related symptoms and/or death from any cause or initiation of a new anti-neoplastic therapy.

    Time frame: Up to approximately 3.8 years. Data cut at last subject have completed Cycle 27 (28 days per Cycle).

  2. Overall Survival (OS) of Acalabrutinib by Investigator

    Outcome Measure was pre-specified to summarize data per investigator assessment with respect to subject's vital/survival status is presented in the RRF and irrespective of iWWM 3rd or 6th criteria. Kaplan-Meier (K-M) estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive by the given time over all patients at risk.

    Time frame: Primary analysis occur when all subjects have completed Cycle 27 or have discontinued before Cycle 27.

  3. Summary of Duration of Response (DOR)

    DOR is defined as the interval from the first documentation of Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR) or Minor Response (MR) to the earlier of the first documentation of definitive PD or death from any cause. The summary statistics are provided for DOR.

    Time frame: Primary analysis occur when all subjects have completed Cycle 27 or have exit the study

07

Results

Posted Apr 24, 2020

Participant flow

In the original protocol, previously treated subjects were planned to be randomized 1:1 into 2 cohorts: Cohort 1 to receive Acala 100 mg BID for 28 days and Cohort 2 to receive Acala 200 mg once daily (QD) for 28 days. After enrollment started, the dose regimen was amended. The 200 mg QD dose was eliminated, and subjects who were enrolled under the original protocol and received treatment with 200 mg QD were switched to 100 mg BID.

Participant flow — Overall Study
MilestonePreviously Treated (PT) TotalTreatment Naive (TN) Cohort 1
Started9214
200 mg qd71
100 mg bid8513
Completed00
Not completed9214
Withdrew: Death261
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject42
Withdrew: Pi decision52
Withdrew: Study terminated by sponsor548

Outcome measures

PrimaryOverall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria

ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.

Time frame:
Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria
ParticipantsPreviously Treated (N=92)Treatment Naive (N=14)
ORR 6th IWWM criteria (CR+VGPR+PR+MR)8713
CR (6th IWWM criteria)40
VGPR (6th IWWM criteria)210
PR (6th IWWM criteria)5210
MR (6th)102
SecondaryProgression-free Survival (PFS) of Acalabrutinib by Investigator

Kaplan-Meier (K-M) estimates of the PFS assessments and its 95% confidence interval are provided using both modified 3rd and 6th IWWM criteria by investigator. K-M estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive or have not progressed by the given time over all patients at risk. Per 6th IWWM criteria, the progressive disease is defined as \>= 25% increase in serum IgM level with an absolute increase of at least 500 mg/dL from lowest nadir (requires confirmation on at least 2 consecutive measurements at least 4 weeks apart) and/or progression of clinical features attributable to the disease. Per modified 3rd IWWM criteria, besides IgM requirement as 6th criteria, it could also includes progression of clinically significant disease related symptoms and/or death from any cause or initiation of a new anti-neoplastic therapy.

Time frame:
Up to approximately 3.8 years. Data cut at last subject have completed Cycle 27 (28 days per Cycle).
Reported as:
Number · percentage of subjects
Progression-free Survival (PFS) of Acalabrutinib by Investigator
percentage of subjectsPreviously Treated (N=92)Treatment Naive (N=14)
K-M Point Est. for PFS by 6th IWWM criteria81.9 (72.1 to 88.5)90.0 (47.3 to 98.5)
K-M Point Est. for PFS by 3rd IWWM criteria81.9 (72.1 to 88.5)90.0 (47.3 to 98.5)
SecondaryOverall Survival (OS) of Acalabrutinib by Investigator

Outcome Measure was pre-specified to summarize data per investigator assessment with respect to subject's vital/survival status is presented in the RRF and irrespective of iWWM 3rd or 6th criteria. Kaplan-Meier (K-M) estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive by the given time over all patients at risk.

Time frame:
Primary analysis occur when all subjects have completed Cycle 27 or have discontinued before Cycle 27.
Reported as:
Number · Percentage of subjects
Overall Survival (OS) of Acalabrutinib by Investigator
Percentage of subjectsPreviously Treated (N=92)Treatment Naive (N=14)
Overall Survival (OS) of Acalabrutinib by Investigator89.0 (80.6 to 93.9)90.9 (50.8 to 98.7)
SecondarySummary of Duration of Response (DOR)

DOR is defined as the interval from the first documentation of Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR) or Minor Response (MR) to the earlier of the first documentation of definitive PD or death from any cause. The summary statistics are provided for DOR.

Time frame:
Primary analysis occur when all subjects have completed Cycle 27 or have exit the study
Reported as:
Mean · months
Summary of Duration of Response (DOR)
monthsPreviously Treated (N=92)Treatment Naive (N=14)
DOR by Modified 3rd IWWM criteria21.9 ± 8.119.6 ± 8.41
DOR by 6th IWWM Criteria21.7 ± 8.1119.5 ± 8.45
PrimaryOverall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria

ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.

Time frame:
Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria
ParticipantsPreviously Treated (N=92)Treatment Naive (N=14)
ORR 3rd IWWM criteria (CR+VGPR+PR+MR)8713
CR (IWWM 3rd criteria)20
VGPR (IWWM 3rd criteria)381
PR (IWWM 3rd criteria)3510
MR (IWWM 3rd criteria)122

Adverse events

Collected over Reported Adverse Events (AEs) include events from the first dose of study drug until 30 days after the last dose of the study drug or start of a new anti-cancer therapy (whichever came first), assessed up to approximately 6 years and 7 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Previously Treated (PT) Cohort 126/87 (29.9%)56/87 (64.4%)87/87 (100%)
Previously Treated (PT) Cohort 20/5 (0%)3/5 (60%)5/5 (100%)
Previously Treated (PT) Total26/92 (28.3%)59/92 (64.1%)92/92 (100%)
Treatment Naive (TN) Cohort 11/13 (7.7%)9/13 (69.2%)13/13 (100%)
Treatment Naive (TN) Cohort 20/1 (0%)0/1 (0%)1/1 (100%)
Treatment Naive (TN) Total1/14 (7.1%)9/14 (64.3%)14/14 (100%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventPreviously Treated (PT) Cohort 1Previously Treated (PT) Cohort 2Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Treatment Naive (TN) Cohort 2Treatment Naive (TN) Total
PyrexiaGeneral disorders4/871/55/920/130/10/14
CellulitisInfections and infestations3/871/54/920/130/10/14
VasculitisVascular disorders0/871/51/920/130/10/14
PneumoniaInfections and infestations11/870/511/920/130/10/14
Lower respiratory tract infectionInfections and infestations10/870/510/920/130/10/14
Cardiac failure congestiveCardiac disorders0/870/50/921/130/11/14
Coronary artery diseaseCardiac disorders0/870/50/921/130/11/14
Myocardial ischaemiaCardiac disorders0/870/50/921/130/11/14
Urinary tract infectionInfections and infestations3/870/53/921/130/11/14
FallInjury, poisoning and procedural complications2/870/52/921/130/11/14
Most frequent other events
Showing 10 of 460
Most frequent other events
EventPreviously Treated (PT) Cohort 1Previously Treated (PT) Cohort 2Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Treatment Naive (TN) Cohort 2Treatment Naive (TN) Total
Abdominal discomfortGastrointestinal disorders5/871/56/920/131/11/14
Abdominal pain upperGastrointestinal disorders6/870/56/921/131/12/14
ConstipationGastrointestinal disorders22/871/523/923/131/14/14
GastritisGastrointestinal disorders1/870/51/920/131/11/14
NauseaGastrointestinal disorders19/872/521/924/131/15/14
Influenza like illnessGeneral disorders4/872/56/922/131/13/14
Upper respiratory tract infectionInfections and infestations24/873/527/923/131/14/14
Alanine aminotransferase increasedInvestigations4/871/55/921/131/12/14
Aspartate aminotransferase increasedInvestigations2/871/53/921/131/12/14
Weight decreasedInvestigations6/870/56/920/131/11/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Total
Mean68.7 ± 9.870.0 ± 13.068.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Total
Female29433
Male631073
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Total
Hispanic or Latino101
Not Hispanic or Latino801494
Unknown or Not Reported11011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White801494
More than one race101
Unknown or Not Reported909
Region of Enrollment
Region of Enrollment(participants)Previously Treated (PT) TotalTreatment Naive (TN) Cohort 1Total
USA19928
United Kingdom50555
Netherlands707
Italy505
Greece303
France808
08

Study locations

38 sites
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Bedford, Texas 76022, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Vancouver, Washington 98684, United States
  • Research Site
    Aurillac, 15002, France
  • Research Site
    Clermond Ferrand, 63003, France
  • Research Site
    Marseille, 13273, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Pierre-Bénite, 69495, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Reims, 51092, France
  • Research Site
    Rennes, 35000, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Vandœuvre-lès-Nancy, 54500, France
  • Research Site
    Athens, 11528, Greece
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Novara, 28100, Italy
  • Research Site
    Amsterdam, 1105AZ, Netherlands
  • Research Site
    Utrecht, 2508GA, Netherlands
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    Bournemouth, BH7 7DW, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    Leicester, LE1 7RH, United Kingdom
  • Research Site
    London, NW1 2BU, United Kingdom
  • Research Site
    London, SW3 6JJ, United Kingdom
  • Research Site
    Oxford, OX3 7LE, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
  • Research Site
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R, Li Y, Rule S, Furman RR. Acalabrutinib in Waldenstrom macroglobulinemia yields durable responses with 5 years of follow-up. Blood Adv. 2026 Jul 28;10(14):5058-5069. doi: 10.1182/bloodadvances.2025017713. PubMed 41985004 ↗
  • Alfaifi A, Bahashwan S, Alsaadi M, Ageel AH, Ahmed HH, Fatima K, Malhan H, Qadri I, Almehdar H. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies. Adv Hematol. 2024 Nov 12;2024:5948170. doi: 10.1155/2024/5948170. eCollection 2024. PubMed 39563886 ↗
  • Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8. Epub 2019 Dec 19. PubMed 31866281 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Oct 2019, 60 months.

Results were first posted in Apr 2020, 6 months after primary completion.

Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2014
First posted
Jul 3, 2014
StartActual
Sep 11, 2014
Primary completionActual
Oct 1, 2019
CompletionEst.
Dec 31, 2026
Results first posted
Apr 24, 2020
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02180724
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jul 3, 2014
Start date
Sep 11, 2014
Primary completion
Oct 1, 2019
Completion
Dec 31, 2026 (estimated)
Results posted
Apr 24, 2020
Last update
Sep 14, 2026

Study contacts

AstraZeneca Clinical study Information Center
study director · 1-877-240-9479 information.center@astrazeneca.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion